Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 545Lung Neoplasms 240Small Cell Lung Carcinoma 106Mesothelioma, Malignant 57Adenocarcinoma of Lung 41Mesothelioma 35Neoplasms 27Neoplasm Metastasis 25Colorectal Neoplasms 22Carcinoma 17Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 15Adenocarcinoma, Bronchiolo-Alveolar 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Stomach Neoplasms 12Pancreatic Neoplasms 12Non-Squamous Non-Small Cell Lung Cancer 12Head and Neck Neoplasms 12Pleural Effusion, Malignant 8Melanoma 8Breast Neoplasms 8Sarcoma 7Extensive Stage Small Cell Lung Cancer 7Triple Negative Breast Neoplasms 6Thymoma 6Solitary Fibrous Tumor, Pleural 6NSCLC 6Endometrial Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Colonic Neoplasms 6

Interventions

SRA737 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia × Cisplatin × Thoracic × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡